Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

NCT05143528 is registered in ClinicalTrials.gov with KeifeRx, LLC as lead sponsor.

NCT NCT05143528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05143528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)
Lead sponsor
KeifeRx, LLC
Phase
Phase 3
Overall status
Unknown status
Start date
February 1, 2022
Completion date
June 1, 2026
Enrollment
1,275 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease